737-P: Acute Healthcare Utilization, Mortality, and Cardiovascular Events following GLP-1-RA Initiation by Patients with Advanced Chronic Kidney Disease—A Real-World Comparative Study

Introduction 0.01) with time-to- death analysis showing a HR of 0.86 (95%CI: 0.82-0.90, p 0.001). There was no significant difference in cardiovascular events between groups (OR 0.98, 95% CI 0.92 to 1.06, p=0.66). Conclusions: Use of GLP1-RA in patients with advanced CKD was associated with lower annual rate of acute healthcare utilization and decreased all-cause mortality. There was no significant difference in cardiovascular events between the matched groups. Disclosure S. Zhang: Stock/Shareholder; Eli Lilly and Company, Novo Nordisk, Amgen Inc. F. Sidra: None. C.A. Alvarez: Research Support; Boehringer-Ingelheim, Bristol-Myers Squibb Company, Merck Altimmune, Astra Zeneca, Bayer, Biomea, Boehringer-Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen/J NovoNordisk, Sanofi, Mylan, Boehringer-Ingelheim. Consultant; TERNS Pharma, The Comm Group, Valeritas, WebMD, and Zealand Pharma. I. Mansi: None.